Answer
Sofosbuvir/Velpatasvir Gilead increases rosuvastatin concentrations and the risk of myopathy, including rhabdomyolysis; the interaction was studied only with velpatasvir, and rosuvastatin may be co-administered at a dose not exceeding 10 mg.
Sources for this answer
- Sofosbuvir/Velpatasvir Gilead 400 mg/100 mg film coated tablets.Gilead Sciences Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 22Document updated
Sources checked